News

Deep learning predicts CRISPR off-target effects

A new computational framework called CCLMoff uses deep learning and RNA language models to predict off-target effects in CRISPR-CAS9 genome editing with improved accuracy across diverse datasets. The tool addresses a critical limitation in current prediction methods that perform poorly on previously unseen guide RNA sequences.

By: Gorm Palmgren - Jun. 10, 2025
News

Off-target effects remain a significant challenge in CRISPR-CAS9 therapeutics, as the system can tolerate sequence mismatches and structural variations at unintended genomic sites. While CRISPR-CAS9 offers remarkable potential for treating monogenic diseases through single-intervention therapies, existing computational methods for predicting these unwanted effects are typically restricted to specifically designed single-guide RNAs and show limited performance when applied to novel sequences.

The researchers developed CCLMoff by incorporating a pre-trained RNA language model from RNAcentral, enabling the framework to capture complex sequence relationships between guide RNAs and their potential target sites. Training on a comprehensive, updated dataset allowed CCLMoff to demonstrate superior generalization capabilities across multiple next-generation sequencing-based detection datasets.

The model's interpretability features confirmed the biological significance of the seed region in guide RNA targeting, validating an established understanding of CRISPR-CAS9 mechanics whilst providing enhanced analytical capabilities.

This advancement represents progress towards developing comprehensive, end-to-end guide RNA design platforms that could improve both precision and efficiency in CRISPR-CAS9 therapeutic applications.

The study was led by Dongsheng Tang at Foshan University, China, and it was published on 6 July in Communications Biology.

To get more CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNewsHashtagAI in genome editingHashtagOff-target

CLINICAL TRIALS
Indicator
IND Enabling
Phase I
Phase II
Phase III
Metastatic Melanoma, (NCT06783270)
Sponsors:
Inge Marie Svane
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine